Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection
Authors:
- Felix GeeraedtsFGFelix Geeraedts
- Wouter ter VeerWVWouter ter Veer
- Jeroen MedemaJMJeroen Medema
- Jan WilschutJWJan Wilschut
- Anke HuckriedeAHAnke Huckriede
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- The annual impact of seasonal influenza in the US: Measuring disease burden and costsVaccine, 2007
- Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysisThe Lancet, 2006
- Vaccines for Seasonal and Pandemic InfluenzaThe Journal of Infectious Diseases, 2006
- Avian Influenza Virus Infections in HumansChest, 2006
- Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndromeProceedings of the National Academy of Sciences, 2004
- Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trialThe Lancet, 2003
- Influenza: vaccination and treatmentEuropean Respiratory Journal, 2001
- Human infection with influenza H9N2The Lancet, 1999
- Adjuvants—a classification and review of their modes of actionVaccine, 1997
- Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactionsJournal of Biological Standardization, 1979